首页> 外文期刊>Brachytherapy >Intraoperative high-dose-rate brachytherapy using dose painting technique: Evaluation of safety and preliminary clinical outcomes
【24h】

Intraoperative high-dose-rate brachytherapy using dose painting technique: Evaluation of safety and preliminary clinical outcomes

机译:术中使用剂量绘画技术进行大剂量近距离放射治疗:安全性评估和初步临床结果

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Intraoperative radiation therapy (IORT) allows delivery of tumoricidal doses of radiation to areas of potential residual microscopic disease while minimizing doses to normal tissues. IORT using high-dose-rate (HDR) brachytherapy allows dose modulation and delivery of concomitant boosts to high-risk areas. This study describes a novel technique of HDR-IORT with dose painting (DP) (HDR-IORT-DP) and evaluates the clinical outcomes. Methods and Materials: Sixteen patients with recurrent cancers received HDR-IORT-DP at the time of radical resection. Of these patients, 13 had colorectal cancer, 2 had head and neck cancer, and 1 had a gynecologic malignancy. All received external beam radiation previously. Negative margin (R0) was obtained in 12 patients (75%) and microscopically positive margins (R1) in 4 patients (25%). Results: The median total target and boost area were 45 and 8.5cm2, and HDR-IORT and boost dose were 1500 and 1750cGy, respectively. Median followup was 14.9 months. The 2-year local control and overall survival were 80% and 20%, respectively. Eleven patients (69%) developed distant metastasis and were deceased at the time of the last followup. A total of 13 patients (19%) developed Grade 3 toxicity related to HDR-IORT; no grade 4+ toxicities were observed. Conclusions: HDR-IORT-DP technique is feasible, safe, and allows for dose escalation in locally advanced or recurrent previously irradiated tumors. To our knowledge, this is the first clinical report on HDR-IORT-DP. Further studies are warranted to evaluate efficacy in a larger patient cohort. Local control was encouraging in our patients. ? 2013 American Brachytherapy Society.
机译:目的:术中放射疗法(IORT)允许向潜在的残留显微疾病区域递送放射剂量的肿瘤,同时将对正常组织的剂量降至最低。使用高剂量率(HDR)近距离放射疗法的IORT可以调节剂量并将伴随的增强作用传递到高风险区域。这项研究描述了一种具有剂量绘画(DP)(HDR-IORT-DP)的HDR-IORT的新技术,并评估了临床结果。方法和材料:16例复发性癌症患者在根治性切除时接受了HDR-IORT-DP。在这些患者中,13例患有大肠癌,2例患有头颈部癌,1例患有妇科恶性肿瘤。所有先前都接收到外部光束辐射。 12例患者(75%)获得负切缘(R0),4例患者(25%)获得镜下阳性切缘(R1)。结果:中位总目标和增强区域分别为45和8.5cm2,HDR-IORT和增强剂量分别为1500和1750cGy。中位随访时间为14.9个月。 2年局部控制率和总生存率分别为80%和20%。 11例患者(69%)发生远处转移并在上次随访时死亡。共有13名患者(19%)出现了与HDR-IORT相关的3级毒性;没有观察到4级以上的毒性。结论:HDR-IORT-DP技术是可行,安全的,并允许在局部晚期或复发的先前照射的肿瘤中增加剂量。就我们所知,这是有关HDR-IORT-DP的第一份临床报告。有必要做进一步的研究来评估在更大的患者队列中的疗效。在我们的患者中,局部控制令人鼓舞。 ? 2013美国近距离放射治疗学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号